CSL Valuation

Is CSJ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CSJ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CSJ (CHF180.92) is trading below our estimate of fair value (CHF236.67)

Significantly Below Fair Value: CSJ is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CSJ?

Key metric: As CSJ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CSJ. This is calculated by dividing CSJ's market cap by their current earnings.
What is CSJ's PE Ratio?
PE Ratio	37.1x
Earnings	US$2.64b
Market Cap	US$97.29b

CSJ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.4x
Enterprise Value/EBITDA	23.8x
PEG Ratio	2.8x

Price to Earnings Ratio vs Peers

How does CSJ's PE Ratio compare to its peers?

The above table shows the PE ratio for CSJ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	29.9x
LONN Lonza Group	65.2x	23.8%	CHF 37.3b
NOVN Novartis	18x	7.0%	CHF 185.4b
ROG Roche Holding	19.1x	11.2%	CHF 202.8b
REGN Regeneron Pharmaceuticals	17.4x	7.6%	US$81.0b
CSJ CSL	37.1x	13.1%	CHF 144.9b

Price-To-Earnings vs Peers: CSJ is good value based on its Price-To-Earnings Ratio (37.1x) compared to the peer average (53.1x).

Price to Earnings Ratio vs Industry

How does CSJ's PE Ratio compare vs other companies in the European Biotechs Industry?

5 Companies	Price / Earnings	Estimated Growth	Market Cap

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: CSJ is expensive based on its Price-To-Earnings Ratio (37.1x) compared to the European Biotechs industry average (24.1x).

Price to Earnings Ratio vs Fair Ratio

What is CSJ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CSJ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	37.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CSJ's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Roche Holding

CHF 202.8b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

CHF 268.00

1.4%

7.5%

Roche Holding

CHF 202.8b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

ROG

CHF 252.50

1.3%

6.8%

Bristol-Myers Squibb

US$100.3b

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

BMY

US$54.24